Wetin yu nid fɔ no bɔt Aduhelm (Aducanumab) fɔ Alzaima sik

Wɔd nɔ go ebul fɔ tɔk bɔt aw wi kin fil bad ɛn nɔ ebul fɔ ɛp wi we wi pɔsin we wi lɛk, sɔntɛm in mama, papa, ɔ padi, gɛt wan sik we dɛn kɔl Alzaima , we kin mek wi nɔ ebul fɔ mɛmba tin. Dɔktɔ ɛn sayɛnsman dɛn ɔlsay na di wɔl de wok tranga wan fɔ fɛn mɛrɛsin fɔ dis sik. As a rizulyt of dis kain efot, di wold stat to tok abaut di drug Aducanumab , we kom anda di brand nem Aduhelm. Bɔt pan ɔl we bɔku pipul dɛn bin de op fɔ dis drɔg, bɔku pipul dɛn bin de agyu bak. Naw dɛn dɔn stɔp fɔ mek dis mɛrɛsin. So tide, lɛ wi tɔk bɔt wetin dis Aduhelm bi, aw i wok, ɛn wetin mek i nɔ de igen.

Fɔ tɔk am simpul wan, wetin na dis Aduhelm (Aducanumab)?

Aduhelm na wan mɛrɛsin wae dɛn kin gi to pipul dɛm wae gɛt di fɔs stej wae gɛt Alzaima, dat na, dɛm wae gɛt smɔl smɔl prɔblɛm wit dɛn maynd . I de pan wan spɛshal klas ɔf drɔgs we dɛn kɔl monoklɔnal antibodi .

Imajin, we Alzaima sik bigin, wan kayn prɔtin we dɛn kɔl amyloid kin gɛda bitwin di nɛv sɛl dɛn na wi bren, ɛn i kin put insɛf lɛk dɔti. Wi kin kɔl dis amilɔyd plek dɛn . Dɛn plek ya kin pwɛl di bren sɛl dɛn ɛn mek dɛn day. di men wok we di Aduhelm dכg de du na fכ no di amyloid plek dεm we de kכmכt na di bren εn εp di bכdi fכ pul dεm.

Di US FDA bin gri fɔ di mɛrɛsin insay wan we we nɔ kɔmɔn, ɛn dɛn nɔ bin pe atɛnshɔn to wetin di ɛjɛnsyi in yon advayz bɔd bin se. Dis bin mek sɔm pipul dɛn we sabi bɔt mɛrɛsin bin aks if dɛn nid fɔ du mɔ risach bɔt aw di mɛrɛsin sef ɛn aw i go wok.

Bɔt di kɔmni we mek dis mɛrɛsin bin stɔp fɔ mek am kpatakpata insay 2024. Wi go si wetin mek leta.

Aw dis mɛrɛsin de wok na di bɔdi?

Dis na drɔg we dɛn kin gi wan tɛm insay di mɔnt tru IV infushɔn . As wi bin dɔn tɔk, wan pan di men sayn dɛm fɔ Alzaima sik na we wan prɔtin we dɛn kɔl amyloid-beta kin gɛda na di bren, we kin mek plek. Dis kin mek di bren sɛl dɛn day, we na di men tin we kin mek pɔsin nɔ ebul fɔ mɛmba tin ɛn chenj di we aw i de biev.

Sayɛnsman dɛn bin tink se if dɛn pul di plek dis we, di bren sɛl dɛn go stɔp fɔ day ɛn dɛn go ebul fɔ kɔntrol di we aw pɔsin de mɛmba ɛn tink mɔ we i de tink.

Yu tink se dis mɛrɛsin rili de wok? Wetin mek dɛn de agyu da kayn we de bɔt am?

Dis na di kwɛstyɔn we bɔku pipul dɛn gɛt. Dɛn bin du tu big stɔdi fɔ chɛk aw di Aduhelm drɔg de wok fayn.

1. Fɔs stכdi: Dis sho se di drɔg we dɛn kɔl Aduhelm de ridyus di amɔnt ɔf amyloid pleks na di bren. I bin slo bak smɔl di rit we di mɛmori ɛn ebul fɔ du ɛvride wok pan di wan dɛn we bin de tek ay doz pan di mɛrɛsin. Bɔt di mɛrɛsin nɔ bin ebul fɔ stɔp ɔ rivɛns di sik.

2. Sɛkɔn stɔdi: Dis stɔdi nɔ sho ɛni bɛnifit to di sik pipul dɛn. So, dɛn bin stɔp dis stɔdi midul.

Di tin dɛn we dɛn bin fɛn frɔm da wan stɔdi de nɔmɔ nɔ bin du fɔ mek di FDA advayz bɔd satisfay. Bɔt di FDA disayd fɔ gri fɔ di mɛrɛsin. Bɔt di sem tɛm, i gi Biogen, di kɔmni we de mek di mɛrɛsin, nayn ia fɔ du ɔda stɔdi fɔ kɔnfirm se di mɛrɛsin de wok. Dis aprɔval we dɛn bin gri fɔ wantɛm wantɛm bin mek bɔku pipul dɛn bigin fɔ agyu bɔt am, ɛn sɔm big big ɔspitul sistɛm dɛn bin disayd nɔ fɔ gi am to dɛn pasɛnt dɛn te dɛn gɛt mɔ infɔmeshɔn bɔt di mɛrɛsin.

Difrɛns bitwin Aducanumab ɛn Lecanemab

Wan ɔda mɛrɛsin de we dɛn kɔl Lecanemab (Leqembi) we fiba Aducanumab (Aduhelm). I de bak pan wan antibodi we de mek pɔsin gɛt wan sik. dis tu de wok bay we dεn de tכk bכt di amyloid protin dεm na di bren. Bɔt, smɔl difrɛns de pan di we aw dɛn de wok. dat min se dεn tu dכg dεm ya de wok na tu difrεn stej dεm na di prכsεs fכ mek amyloid plek. Lecanemab bin gɛt FDA aprɔval insay 2023. Risach dɔn sho se i kin slo di sik fɔ go bifo bay lɛk 20%-30%.

Wetin na di sayd ɛfɛkt dɛm we Aducanumab gɛt?

Lɛk ɛni mɛrɛsin, Aducanumab kin mek yu gɛt sayd ɛfɛkt . Sɔm pan dɛn tin ya kin siriɔs, so i impɔtant fɔ no bɔt dɛn.

Di tin we impɔtant pas ɔl na dat, if pɔsin we de tek dis kayn mɛrɛsin gɛt ɛnitin we nɔ kɔmɔn, i fɔ tɛl in dɔktɔ wantɛm wantɛm.

So wetin mek dɛn bin stɔp fɔ tek dis mɛrɛsin?

Insay Janwari 2024, Biogen bin anɔys se dɛn go stɔp fɔ mek ɛn sɛl Aducanumab ɔltogɛda. Bɔku pipul dɛn bin tink se dis na bikɔs dɛn de wɔri bɔt sef ɔ bikɔs dɛn nɔ ebul fɔ du am. Bɔt nɔto dat na di rial rizin.

Di kɔmni ɛksplen se dɛn mek dis muv bikɔs dɛn disayd fɔ pe atɛnshɔn pan in risɔs (mɔni, risach tim, ɛn ɔda tin dɛn) fɔ divɛlɔp ɛn promot ɔda Alzaima mɛrɛsin, mɔ di mɛrɛsin dɛn lɛk Lecanemab. Dat min se, dis na bin biznɛs ɛn risɔs manejmɛnt disizhɔn, ɛn nɔto bin disizhɔn we dɛn mek bikɔs dɛn bin de wɔri bɔt di drɔg in sef ɔ if i wok.

Wit dis disishun, afta Novɛmba 1, 2024, ivin pasɛnt dɛn we dɔn gɛt dis mɛrɛsin pan prɛskrishɔn nɔ go ebul fɔ gɛt am igen.